SEC Comment Letter 0000000000-24-003745 to Aquestive Therapeutics, Inc. (AQST) (CIK 0001398733) (AQST)
Aquestive Therapeutics, Inc. (AQST) (CIK 0001398733)
Date: April 8, 2024 · CIK: 0001398733 · Accession: 0000000000-24-003745
AI Filing Summary & Sentiment
File numbers found in text: 333-278498
Letter
United States securities and exchange commission logo April 8, 2024 A. Earnest Toth, Jr. Chief Financial Officer Aquestive Therapeutics, Inc. 30 Technology Drive Warren, NJ 07059 Re:Aquestive Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-278498 Filed April 3, 2024 Dear A. Earnest Toth: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Anna Tomcyzk
Show Raw Text
United States securities and exchange commission logo
April 8, 2024
A. Earnest Toth, Jr.
Chief Financial Officer
Aquestive Therapeutics, Inc.
30 Technology Drive
Warren, NJ 07059
Re:Aquestive Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-278498
Filed April 3, 2024
Dear A. Earnest Toth:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Anna Tomcyzk